Head and neck cancer - emerging targeted therapies

Area of Science:

• Oncology
• Cancer Therapeutics
• Head and Neck Cancer Research

Background:

• Systemic therapy is the primary treatment for recurrent and metastatic head and neck squamous cell cancers (HNSCC).
• Current effective treatments are limited, including platinum combinations, anti-PD-1 agents, and cetuximab targeting EGFR.
• There is a significant unmet need for novel and more effective therapeutic strategies.

Purpose of the Study:

• To review the clinical limitations of current approved systemic therapies for R/M HNSCC.
• To explore emerging targeted agents and novel therapeutic approaches in development for HNSCC.
• To highlight ongoing clinical trials investigating targeted therapies in advanced HNSCC.

Main Methods:

• Literature review of current systemic therapies for HNSCC.
• Analysis of recent clinical trial data for novel agents.
• Exploration of emerging therapeutic targets and mechanisms of action.

Main Results:

• Current therapies like platinum, anti-PD-1, and cetuximab have limitations in efficacy for R/M HNSCC.
• New agents targeting alternate oncogenic pathways are under investigation.
• Novel mechanisms including bi-specific antibodies and antibody-drug conjugates show promise.

Conclusions:

• There is a critical need for improved systemic treatments for R/M HNSCC.
• Emerging targeted therapies and novel drug conjugates represent promising avenues for future treatment.
• Ongoing clinical trials are essential for advancing the care of patients with advanced HNSCC.